Control Empresarial De Capital Acquires 14,000 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

ProKidney Corp. (NASDAQ:PROKGet Free Report) insider Control Empresarial De Capital purchased 14,000 shares of the company’s stock in a transaction that occurred on Friday, March 22nd. The shares were purchased at an average cost of $1.40 per share, for a total transaction of $19,600.00. Following the completion of the transaction, the insider now directly owns 63,265,645 shares of the company’s stock, valued at $88,571,903. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Control Empresarial De Capital also recently made the following trade(s):

  • On Monday, March 25th, Control Empresarial De Capital purchased 30,000 shares of ProKidney stock. The shares were bought at an average price of $1.43 per share, with a total value of $42,900.00.
  • On Wednesday, March 20th, Control Empresarial De Capital purchased 33,000 shares of ProKidney stock. The stock was acquired at an average cost of $1.40 per share, for a total transaction of $46,200.00.
  • On Wednesday, March 13th, Control Empresarial De Capital acquired 50,000 shares of ProKidney stock. The stock was purchased at an average price of $1.50 per share, with a total value of $75,000.00.

ProKidney Trading Up 7.0 %

Shares of ProKidney stock opened at $4.06 on Friday. ProKidney Corp. has a 1 year low of $1.12 and a 1 year high of $13.51. The company has a 50 day simple moving average of $2.09 and a two-hundred day simple moving average of $1.77.

ProKidney (NASDAQ:PROKGet Free Report) last released its earnings results on Thursday, March 21st. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. As a group, equities research analysts expect that ProKidney Corp. will post -0.61 EPS for the current year.

Analysts Set New Price Targets

Separately, Morgan Stanley initiated coverage on shares of ProKidney in a report on Thursday, March 7th. They issued an “equal weight” rating and a $3.00 price target on the stock.

View Our Latest Stock Analysis on ProKidney

Hedge Funds Weigh In On ProKidney

A number of large investors have recently modified their holdings of PROK. Federated Hermes Inc. grew its position in ProKidney by 10,984.7% during the fourth quarter. Federated Hermes Inc. now owns 113,286 shares of the company’s stock valued at $202,000 after acquiring an additional 112,264 shares during the last quarter. Jump Financial LLC bought a new position in shares of ProKidney during the 3rd quarter valued at $216,000. SG Americas Securities LLC raised its position in ProKidney by 174.2% in the 4th quarter. SG Americas Securities LLC now owns 46,829 shares of the company’s stock worth $83,000 after purchasing an additional 29,749 shares during the period. Finally, Zullo Investment Group Inc. purchased a new stake in ProKidney during the first quarter valued at about $32,000. 51.59% of the stock is owned by hedge funds and other institutional investors.

About ProKidney

(Get Free Report)

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.

Featured Stories

Insider Buying and Selling by Quarter for ProKidney (NASDAQ:PROK)

Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.